查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
原發性膽汁性膽管炎治療藥物市場：依藥物類型、通路劃分：2023-2032年全球機會分析與產業預測
市場調查報告書
商品編碼
1344488

原發性膽汁性膽管炎治療藥物市場：依藥物類型、通路劃分：2023-2032年全球機會分析與產業預測

Primary Biliary Cholangitis Therapeutics Market By Drug type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 229 Pages | 商品交期: 2-3個工作天內

價格

2022年原發性膽汁性膽管炎治療藥物市值為6.8395億美元，預計到2032年將達到14億美元，2023年至2032年的複合年增長率為7.1%。

COVID-19 大流行擾亂了全球供應鏈，包括藥品製造和分銷。 生產設施的流動限制、封鎖和勞動力減少導致原發性膽汁性膽管炎 (PBC) 治療藥物的生產和銷售延誤。 因此，COVID-19的爆發對原發性膽汁性膽管炎治療藥物市場產生了負面影響。

原發性膽汁性膽管炎治療市場-IMG1

亞太地區原發性膽汁性膽管炎病例數量的增加推動了原發性膽汁性膽管炎治療藥物的市場份額不斷增長。 例如，根據2021年1月發表的綜述文章《原發性膽汁性膽管炎的當前認知》顯示，日本人口中PBC的盛行率為每10萬人中33.8人。 根據 Research Outreach 上的一篇文章稱，截至 2020 年 5 月，日本估計有超過 37,000 人患有原發性膽汁性膽管炎 (PBC)。 原發性膽汁性膽管炎病例的增加增加了對原發性膽汁性膽管炎治療藥物的需求。

此外，製藥業繼續投資研發，以更好地了解 PBC 的潛在機制並開發創新療法。 這包括探索新的藥物標靶、進行臨床試驗和研究聯合療法。 因此，增加膽汁性膽管炎一線藥物的研發將推動預測期內膽汁性膽管炎一線藥物市場規模的成長。

PBC也是一種慢性疾病，需要長期治療。 儘管有特定的治療方法，但對更有效的治療方法的需求仍然未得到滿足，特別是對於對現有治療沒有充分反應的患者。 這增加了對創新和標靶治療的需求，以滿足原發性膽管炎未滿足的醫療需求，推動膽汁性膽管炎藥物的市場份額成長。

然而，對原發性膽汁性膽管炎 (PBC) 的認識不足、PBC 的早期診斷以及有限的治療選擇預計將阻礙原發性膽汁性膽管炎治療藥物市場的成長。 主要參與者更多地採用收購、產品批准和協議等關鍵策略以及一線膽汁性膽管炎藥物的進步將促進一線膽汁性膽管炎藥物行業在預測期內的增長。將為您鋪平道路。

目錄

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 原發性膽汁性膽管炎患者增加
      • 加強研發力度
    • 抑制因素
      • 缺乏早期診斷且治療選擇有限
    • 機會
      • 更採用關鍵策略
  • 新冠肺炎 (COVID-19) 市場影響分析

第四章原發性膽汁性膽管炎治療藥物市場：依藥物類型劃分

  • 摘要
  • 主要治療藥物
  • 二級治療藥物

第五章原發性膽汁性膽管炎治療藥物市場：依通路劃分

  • 摘要
  • 醫院藥房
  • 藥局和零售藥局
  • 網路藥局

第六章原發性膽汁性膽管炎治療藥物市場：依地區劃分

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 印度
    • 韓國
    • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他領域

第七章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第八章公司簡介

  • Intercept Pharmaceuticals, Inc.
  • Lupin
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Ltd
  • Leeford Healthcare Limited
  • Alkem Laboratories Ltd.
  • AMAGEN INDIA LIFE SCIENCES
  • GENFIT
  • Ipsen Pharma
  • ABC Farmaceutici S.p.a.
Product Code: A108539

According to a new report published by Allied Market Research, titled, "Primary Biliary Cholangitis Therapeutics Market," The primary biliary cholangitis therapeutics market was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

The COVID-19 pandemic caused disruptions in global supply chains, including pharmaceutical manufacturing and distribution. Restrictions on movement, lockdowns, and reduced workforce in manufacturing facilities led to delays in the production and distribution of primary biliary cholangitis (PBC) therapeutics. Therefore, the COVID-19 outbreak had a negative impact on the primary biliary cholangitis therapeutics market.

Primary Biliary Cholangitis Therapeutics Market - IMG1

Market Dynamics

The growth of the primary biliary cholangitis therapeutics market share is driven by the rise in cases of primary biliary cholangitis in Asia-Pacific. For instance, according to the review article "Current understanding of primary biliary cholangitis", published in January 2021, the point prevalence of PBC was 33.8 per 100,000 in the Japanese population. As per the Research Outreach article, in May 2020, over 37,000 people in Japan are estimated to have primary biliary cholangitis (PBC). Rise in the cases of primary biliary cholangitis has resulted in increased demand for primary biliary cholangitis therapeutics.

Furthermore, the pharmaceutical industry continues to invest in research and development efforts to better understand the underlying mechanisms of PBC and develop innovative therapies. This includes exploring new drug targets, conducting clinical trials, and investigating combination therapies. Therefore, the rise in research and development regarding primary biliary cholangitis therapeutics drives the growth of the primary biliary cholangitis therapeutics market size during the forecast period. in June 2021, HighTide Therapeutics ("HighTide"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, announced that the first patient has been dosed in Phase 2 PRONTO-PBC study of HighTide evaluating first-in-class HTD1801 in adult patients with primary biliary cholangitis (PBC).

Moreover, PBC is a chronic condition that requires long-term management. Despite the availability of certain therapies, there is still an unmet need for more effective treatments, particularly for patients who do not respond adequately to existing therapies. This drives the demand for innovative and targeted therapeutics to address the unmet medical needs in PBC. Hence, such factors drive the growth of the primary biliary cholangitis therapeutics market share.

However, lack of awareness regarding primary biliary cholangitis (PBC), early diagnosis of PBC, and limited treatment options are expected to hinder the growth of primary biliary cholangitis therapeutics market. On the contrary, an increase in the adoption of key strategies such as acquisition, product approval, and agreement by key players and advancements in primary biliary cholangitis therapeutics are expected to open new avenues for the growth of the primary biliary cholangitis therapeutics industry across the world during the forecast period.

The COVID-19 pandemic affected the primary biliary cholangitis therapeutics industry in a negative way, such as various healthcare industries were affected due to postponed of non-emergency services. The pandemic has disrupted research activities, including clinical trials, restrictions on patient recruitment and new product development. However, with relaxation in lockdowns and decline in COVID-19 cases, companies have re-started their processes to meet the demand for primary biliary cholangitis therapeutics. In addition, rise in product approvals, and increase in research and development of advanced medicine of primary biliary cholangitis therapeutics drive the growth of primary biliary cholangitis therapeutics market.

In addition, rise in awareness in pharmaceutical companies, and governments regarding supply chain hinderance of pharmaceutical products drives the growth of primary biliary cholangitis therapeutics market. For instance, government agencies in the U.S. and around the globe learned some tough lessons about the pharmaceutical supply chain after the COVID-19 pandemic landed, causing problems and highlighting weaknesses in key areas. In the session of "U.S. Government Investments in Pharmaceutical Manufacturing and Supply Chain and Future Pandemics for today" at the 2022 BIO International Conference, representatives from the U.S. health agencies shared lessons learned from COVID-19, and how government and industry have collaborated to avoid future supply chain crises. Moreover, the U.S. leaders stated that the government has learned since the beginning of the pandemic, steps taken since arrival of COVID-19, and plans the U.S. has put in place to avoid problems in the future. Thus, such trends are expected to bring stabilization in the market, and subsequently witness pre-pandemic growth rate during the forecast period.

Segmental Overview

The primary biliary cholangitis therapeutics market is segmented on the basis of drug type, distribution channel, and region. On the basis of drug type, the market is bifurcated into primary treatment and secondary treatment. The primary treatment segment is further categorized into obeticholic acid, ursodeoxycholic acid, and others (PPARα/PPARδ agonist, and ileal bile acid transport inhibitors). On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Key Benefits For Stakeholders:

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the primary biliary cholangitis therapeutics market analysis from 2022 to 2032 to identify the prevailing primary biliary cholangitis therapeutics market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the primary biliary cholangitis therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global primary biliary cholangitis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in cases of primary biliary cholangitis
      • 3.4.1.2. Rise in research and development
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of early diagnosis and limited treatment options
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in adoption of key strategies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Primary Drug
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Primary Drug Primary Biliary Cholangitis Therapeutics Market by Type
  • 4.3. Secondary Drug
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital Pharmacies
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Drugs Stores and Retail Pharmacies
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Online Pharmacies
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Drug type
    • 6.2.3. Market size and forecast, by Distribution Channel
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Drug type
      • 6.2.4.1.3. Market size and forecast, by Distribution Channel
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Drug type
      • 6.2.4.2.3. Market size and forecast, by Distribution Channel
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Drug type
      • 6.2.4.3.3. Market size and forecast, by Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Drug type
    • 6.3.3. Market size and forecast, by Distribution Channel
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Drug type
      • 6.3.4.1.3. Market size and forecast, by Distribution Channel
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Drug type
      • 6.3.4.2.3. Market size and forecast, by Distribution Channel
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Drug type
      • 6.3.4.3.3. Market size and forecast, by Distribution Channel
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Drug type
      • 6.3.4.4.3. Market size and forecast, by Distribution Channel
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Drug type
      • 6.3.4.5.3. Market size and forecast, by Distribution Channel
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Drug type
      • 6.3.4.6.3. Market size and forecast, by Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Drug type
    • 6.4.3. Market size and forecast, by Distribution Channel
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Drug type
      • 6.4.4.1.3. Market size and forecast, by Distribution Channel
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Drug type
      • 6.4.4.2.3. Market size and forecast, by Distribution Channel
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Drug type
      • 6.4.4.3.3. Market size and forecast, by Distribution Channel
      • 6.4.4.4. India
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Drug type
      • 6.4.4.4.3. Market size and forecast, by Distribution Channel
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Drug type
      • 6.4.4.5.3. Market size and forecast, by Distribution Channel
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Drug type
      • 6.4.4.6.3. Market size and forecast, by Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Drug type
    • 6.5.3. Market size and forecast, by Distribution Channel
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Drug type
      • 6.5.4.1.3. Market size and forecast, by Distribution Channel
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Drug type
      • 6.5.4.2.3. Market size and forecast, by Distribution Channel
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Drug type
      • 6.5.4.3.3. Market size and forecast, by Distribution Channel
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Drug type
      • 6.5.4.4.3. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Intercept Pharmaceuticals, Inc.
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. Lupin
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Zydus Lifesciences Limited
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Sun Pharmaceutical Industries Ltd
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Leeford Healthcare Limited
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
  • 8.6. Alkem Laboratories Ltd.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. AMAGEN INDIA LIFE SCIENCES
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
  • 8.8. GENFIT
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. Ipsen Pharma
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. ABC Farmaceutici S.p.a.
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR PRIMARY DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL PRIMARY DRUG PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR SECONDARY DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 06. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 13. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 14. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 15. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 16. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 22. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 27. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 37. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 40. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 42. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. INTERCEPT PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 61. INTERCEPT PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 62. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 63. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 64. INTERCEPT PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 65. LUPIN: KEY EXECUTIVES
  • TABLE 66. LUPIN: COMPANY SNAPSHOT
  • TABLE 67. LUPIN: PRODUCT SEGMENTS
  • TABLE 68. LUPIN: PRODUCT PORTFOLIO
  • TABLE 69. LUPIN: KEY STRATERGIES
  • TABLE 70. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 71. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 72. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 73. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
  • TABLE 75. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 76. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 77. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
  • TABLE 78. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 79. LEEFORD HEALTHCARE LIMITED: KEY EXECUTIVES
  • TABLE 80. LEEFORD HEALTHCARE LIMITED: COMPANY SNAPSHOT
  • TABLE 81. LEEFORD HEALTHCARE LIMITED: PRODUCT SEGMENTS
  • TABLE 82. LEEFORD HEALTHCARE LIMITED: PRODUCT PORTFOLIO
  • TABLE 83. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 84. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 85. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 86. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 87. AMAGEN INDIA LIFE SCIENCES: KEY EXECUTIVES
  • TABLE 88. AMAGEN INDIA LIFE SCIENCES: COMPANY SNAPSHOT
  • TABLE 89. AMAGEN INDIA LIFE SCIENCES: PRODUCT SEGMENTS
  • TABLE 90. AMAGEN INDIA LIFE SCIENCES: PRODUCT PORTFOLIO
  • TABLE 91. GENFIT: KEY EXECUTIVES
  • TABLE 92. GENFIT: COMPANY SNAPSHOT
  • TABLE 93. GENFIT: PRODUCT SEGMENTS
  • TABLE 94. GENFIT: PRODUCT PORTFOLIO
  • TABLE 95. GENFIT: KEY STRATERGIES
  • TABLE 96. IPSEN PHARMA: KEY EXECUTIVES
  • TABLE 97. IPSEN PHARMA: COMPANY SNAPSHOT
  • TABLE 98. IPSEN PHARMA: PRODUCT SEGMENTS
  • TABLE 99. IPSEN PHARMA: PRODUCT PORTFOLIO
  • TABLE 100. IPSEN PHARMA: KEY STRATERGIES
  • TABLE 101. ABC FARMACEUTICI S.P.A.: KEY EXECUTIVES
  • TABLE 102. ABC FARMACEUTICI S.P.A.: COMPANY SNAPSHOT
  • TABLE 103. ABC FARMACEUTICI S.P.A.: PRODUCT SEGMENTS
  • TABLE 104. ABC FARMACEUTICI S.P.A.: PRODUCT PORTFOLIO
  • TABLE 105. ABC FARMACEUTICI S.P.A.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET
  • FIGURE 09. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR PRIMARY DRUG, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR SECONDARY DRUG, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY REGION, 2022
  • FIGURE 17. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 18. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 19. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 20. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 40. COMPETITIVE DASHBOARD
  • FIGURE 41. COMPETITIVE HEATMAP: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET
  • FIGURE 42. TOP PLAYER POSITIONING, 2022
  • FIGURE 43. INTERCEPT PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 44. LUPIN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 47. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. SUN PHARMACEUTICAL INDUSTRIES LTD: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 51. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. GENFIT: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. IPSEN PHARMA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. IPSEN PHARMA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. IPSEN PHARMA: REVENUE SHARE BY REGION, 2022 (%)